Journal of Ophthalmology

Journal of Ophthalmology / 2017 / Article

Research Article | Open Access

Volume 2017 |Article ID 7205408 |

Huan Yan, Yanli Peng, Wei Huang, Liyan Gong, Li Li, "The Protective Effects of αB-Crystallin on Ischemia-Reperfusion Injury in the Rat Retina", Journal of Ophthalmology, vol. 2017, Article ID 7205408, 10 pages, 2017.

The Protective Effects of αB-Crystallin on Ischemia-Reperfusion Injury in the Rat Retina

Academic Editor: Jesús Pintor
Received24 Apr 2017
Revised28 Jul 2017
Accepted06 Aug 2017
Published02 Oct 2017


To investigate whether αB-crystallin protects against acute retinal ischemic reperfusion injury (I/R) and elucidate the potential antioxidant mechanisms. Retinal I/R injury was made by elevating the intraocular pressure (IOP) 110 mmHg for 60 min, and αB-crystallin (1 × 10−5 g/L) or vehicle solution was administered intravitreously immediately after I/R injury. The animal was sacrificed 24 h, 1 w, and 1 m after the I/R injury. The retina damage was detected by hematoxylin and eosin (HE) staining and electroretinography (ERG). The level of malondialdehyde (MDA), nitric oxide (NO), and the total superoxide dismutase (T-SOD) was determined. An immunohistochemical study was performed to detect the activation of inducible nitric oxide synthase (iNOS) and NF- (nuclear factor-) kappaB (NF-κB) p65. The decrease of retinal thickness and the number of retinal ganglion cells (RGCs) can be suppressed by αB-crystallin. And the amplitudes of a- and b-wave were remarkably greater without αB-crystallin. Similarly, αB-crystallin also significantly decreased the level of MDA and NO and enhanced the activities of T-SOD. The positive expression of iNOS and NF-kappaB p65 was obviously reduced while treated with αB-crystallin. αB-crystallin can inhibit the expression of NF-κB and its antioxidative effect to protect the retina from I/R injury.

1. Introduction

Retinal ischemia reperfusion (I/R) injury is responsible for several vision-threatening ocular diseases such as retinal vascular occlusion, acute glaucoma, diabetic retinopathy, and retinopathy of prematurity [1, 2]. Pathological changes are involved in I/R, including energy-dependent dysfunction and tissue edema. At present, the postulated pathogenesis of I/R injury is associated with the toxic effect of excitatory amino acids (e.g., glutamate), excessive accumulation of oxygen-free radicals and intracellular calcium overload, proinflammatory factor releasing, and especially the production of reactive oxygen species (ROS) [3].

αB-crystallin is a prominent member of the small heat-shock protein family, which has been documented to distribute in different tissues such as lens, neural retina, retinal pigment epithelium, heart, skeletal muscle, kidney, and brain [46]. As we all know, αB-crystallin is not solely recognized in chaperone effect, it also includes antiangiogenesis and antioxidative stress [79]. Nowadays, emerging evidences demonstrate that αB-crystallin retrieves organs and tissues from the impairment of I/R, including the heart and brain [10, 11]. Nevertheless, there is few research concerning the effect of αB-crystallin to protect retina from the damage of I/R.

Considerable reports have revealed that αB-crystallin has a neuroprotection in the model of optic nerve crush, which can improve the survival of retinal ganglion cells (RGCs) and function of retina [1214]. However, there are few studies demonstrating αB-crystallin protecting retina from injury of ischemic reperfusion. A most recent investigation has proved that αB-crystallin plays a neuroprotective role in retina ischemic reperfusion injury through attenuating the expression of caspase-3 to suppress retina ganglion cell (RGC) death [15]. Furthermore, an increasing number of research has suggested that antioxidant has neuroprotective effect through antioxidation and by modulating NF- (nuclear factor-) kappaB p65 (NF-κB) in retina I/R model [1618]. The purpose of this study is to investigate whether αB-crystallin could prevent retina from I/R injury and further to determine whether this effect is related to antioxidative reaction and downregulation of NF-kappa B.

2. Materials and Methods

2.1. Animals

The study included 72 adult male Sprague-Dawley rats weighing 180–200 g which were purchased from the Laboratory Animal Center of Chongqing Medical University. Institutional ethics committee at Chongqing Medical University approved all animal experiments. Animal care and all experiments were treated in accordance with the Association for Research in Vision and Ophthalmology (ARVO) guidelines for the Use of Animals in Ophthalmic and Vision Research. The animals were kept in laminar flow racks under a stable temperature and humidity condition with 12-hour light/dark cycles.

2.2. Retinal I/R Injury Experiment

Before retinal ischemia reperfusion construction, the animals were anesthetized by an intraperitoneal (i.p.) injection of 3.5% chloral hydrate (1 mL/kg). Topical anesthesia was achieved by using 1 or 2 drops of 0.4% oxybuprocaine hydrochloride (Benoxil, Santen, Japan), and pupillary dilatation was maintained using 0.5% tropicamide (compound tropicamide eye drops, Santen, Japan). Rats were put on a heating blanket to maintain the body temperature at 37°C. After dilation of the pupil, a 27 G needle was inserted into the anterior chamber of the right eye under a microscope, which was connected to a saline reservoir (250 mL). The reservoir was lifted at 150 cm above the eye to increase intraocular pressure (IOP) to 110 mmHg for 60 minutes. Retinal ischemia was confirmed by whitening of the iris and loss of the red reflex of the retina. After 60 minutes, the needle was removed from the anterior chamber and reperfusion was confirmed with observation of iris and fundus vessels. Only the right eye accepted IOP, and ofloxacin ophthalmic gel (0.3%) was applied to the eye through all the experiments. The sham group performed the same procedure except elevating the container.

2.3. Drug Administration

The rats were administrated with αB-crystallin (Sigma-Aldrich, St. Louis, MO, USA; 1 × 10−5 g/L, 5 μL; dissolved in phosphate buffer saline) or vehicle (phosphate buffer saline) via intravitreous injection once immediately after retinal I/R injury. The animals were randomly assigned to three groups, which included sham group, I/R + vehicle group, and I/R + αB-crystallin group. Each group had 4–6 rats.

2.4. Histopathology

The eyes were enucleated () at 24 hours, 1 week, and 1 month after I/R injury, respectively, and fixed in 4% paraformaldehyde for 2 hours at 4°C, and anterior segment was removed. The tissues were dehydrated with10% and 20% sucrose, respectively, for an hour and with 30% overnight. Fixed eyeballs were embedded in optimum cutting temperature compound (Sakura, USA) and cut into 10 μm-thick parallel with the maximal circumference of the eye ball through the optic disc. The tissues were stained with hematoxylin and eosin (HE) and observed under light microscope (Leica, Heidelberg, Germany). Light microscope images were obtained at 400x magnification. To evaluate the damage of retinal ischemia reperfusion, the thickness was measured including total retina thickness, the inner plexiform layer (IPL), the inner nuclear layer (INL), and outer nuclear layers (ONL) and the number of cells in the ganglion cell layer (GCL) was calculated using the linear cell density (cells per 200 μm). All measurements were made with 2 to 3 disc diameters from the optic disc, and 3 sections per eye were averaged.

2.5. Electroretinogram (ERG)

To access the function of retina at 1 week after I/R, the rats () were detected with ERG (RETIport32, Roland, Germany). The rats were dark-adapted over 12 hours and anesthetized with sumianxin II. After anesthetization, the cornea was achieved using 1 or 2 drops of 0.4% oxybuprocaine hydrochloride and pupillary dilatation was maintained using 0.5% tropicamide. The rats were placed on a heating blanket to maintain body temperature at 37°C facing the stimulus at a distance of 20 cm. Stainless steel wire loops (0.1 mm diameter) were placed on the center of the cornea, a reference electrode was connected to the middle of the lower eyelid, and a grounding electrode was placed near the tail. Responses to a light flash (2.5 cd · s/m2) from a photic stimulator were amplified, and the preamplifier bandwidth was set at 0.3–300 Hz. The amplitude of the a-wave was measured from the baseline to the trough, while that of the b-wave was measured from the maximum of the a-wave trough to the peak of the b-wave. The amplitude of oscillatory potentials (Ops) was measured as the sum of the amplitudes of OP1, OP2, OP3, and OP4.

2.6. Determination of the Level of MDA and NO and the Activity of T-SOD

All the eyes (, for each group) were enucleated, and the retina was isolated 24 hours and 1 week after retinal I/R injury. The samples were prepared to 10% homogenized sterile normal saline at the ratio of 1 : 9 according to the weight, and the solution was centrifuged at 2500 rpm for 10 minutes at 4°C. The supernatant was prepared for the following measurements. The 10% homogenates were diluted into 5% for the measurement of malondialdehyde (MDA), and the supernatant was diluted, respectively, into 5% for total superoxide dismutase (T-SOD) and 1% for nitric oxide (NO) and protein concentration. Protein concentrations were detected with the total protein quantitative assay kit (Jiancheng Institute of Biotechnology, Nanjing, China). The levels of MDA were measured by the formation of thiobarbituric acid reactive species with the malondialdehyde assay kit (Jiancheng Institute of Biotechnology, Nanjing, China). The NO was combined with water and oxygen to form nitrates and nitrites whose level indicated the content of NO tested with nitric oxide assay kit (Jiancheng Institute of Biotechnology, Nanjing, China). The T-SOD activity was determined with hydroxylamine assay provided by commercial test kits (Jiancheng Institute of Biotechnology, Nanjing, China). The data were expressed as nanomoles per milligram protein (nM/mgprot) for MDA, micromoles per milligram protein (μmol/mgprot) for NO, and units per milligram protein (U/mgprot) for T-SOD. All of the procedures were performed in ice.

2.7. Immunohistochemistry Staining

OCT-embedded retinal sections were put at room temperature for about an hour and washed (three times, 5 minutes) with PBS, incubated with 3% H2O2 deionized water to make endogenous peroxidase activity inactivate, and blocked the tissue sections in goat serum (Zhongshan Jinqiao Institute of Biotechnology, Beijing, China). Primary antibody inducible nitric oxide synthase (iNOS) (1 : 100; Novus Biological, USA) and NF-kappa B p65 (1 : 300; Biosynthesis Institute of Biotechnology, Beijing, China) were applied to the sections overnight at 4°C, respectively. In the next day, sections were incubated with secondary antibody for 20 minutes at room temperature. Hematoxylin-DAB was used for staining, resulting in a brown signal (Zhongshanjinqiao Institute of Biotechnology, Beijing, China).

2.8. Statistical Analysis

All the data were presented as the mean ± SD. Statistical analyses were carried out using SPSS for Windows version 19.0 (SPSS Inc., Chicago, IL). To determine the significant differences, an analysis of variance (ANOVA) was applied. A was considered to be statistically significant.

3. Results

3.1. αB-Crystallin Protects Rat Retina from Histological Damage and RGC Death Caused by I/R Injury

As shown in Figures 1 and 2, HE-stained retinas were used to access the change of retinal layers at 24 hours, 1 week, and 1 month, respectively, after I/R injury; data was expressed in Table 1. Compared with sham group, the thickness of the retina in I/R ± vehicle group was significantly reduced, which was primarily due to degeneration of cell bodies in the GCL and thinning of the INL, IPL, and ONL. And the changes of rat retinal layers were approximately consistent at 3 time points. The overall retinal thickness in I/R ± vehicle group was reduced by 24%, 24%, and 48%, respectively, compared with the sham group at 24 hours, 1 week, and 1 month after I/R injury (). In I/R + vehicle group, the thickness of IPL, INL, and ONL was decreased by 33%, 28%, and 18%, respectively () at 24 hours post-I/R compared with the sham group (). In consistent with the change of retinal layers, the thickness of IPL, INL, and ONL in I/R + vehicle group was reduced by 32%, 25%, and 28% at 1 week and 53%, 43%, and 43% at 1 month post-I/R, respectively (). The mean density of RGCs in I/R ± vehicle group was obviously lower than that in sham group (7.67 ± 1.51 versus 27.00 ± 1.10, 9.33 ± 2.42 versus 27.67 ± 1.51, and 9.67 ± 1.51 versus 26.67 ± 2.07/200 μm, resp., for 24 hours, 1 week, and 1 month after I/R) ().

GroupThickness (μm)GCL cell number
Each OverallIPLINLONL(200 μm)

Sham158.84 ± 3.7552.86 ± 2.7229.66 ± 1.9949.80 ± 1.4227.00 ± 1.10
24 h I/R + vehicle121.10 ± 3.03a,35.62 ± 2.92a,21.38 ± 1.13a,40.56 ± 0.98a,7.67 ± 1.51a,
24 h I/R + αB144.05 ± 2.55b,45.07 ± 1.68b,24.46 ± 1.61b,48.56 ± 2.66b,15.67 ± 1.97b,
1 w I/R + vehicle120.32 ± 2.14a,36.06 ± 1.41a,22.33 ± 0.93a,35.89 ± 2.15a,9.33 ± 2.42a,
1 w I/R + αB134.03 ± 1.10b,43.98 ± 0.49b,27.68 ± 0.72b,42.42 ± 1.41b,15.00 ± 2.10b,
1 m I/R + vehicle82.83 ± 4.14a,24.67 ± 1.72a,16.77 ± 1.12a,28.23 ± 3.53a,9.67 ± 1.51a,
1 m I/R + αB133.49 ± 1.69b,42.31 ± 1.41b,27.91 ± 0.67b,40.26 ± 2.71b,17.33 ± 1.63b,

aCompared with sham group. bCompared with I/R + vehicle; . INL: inner nuclear layer; IPL: inner plexiform layer; ORL: outer retinal layer; GCL: ganglion cell layer; I/R: ischemia-reperfusion.

Compared with I/R + αB-crystallin group, the overall retinal thickness in I/R + vehicle group, respectively, was significantly decreased by 16%, 10%, and 38% at 3 points () and the thickness of IPL, INL, and ONL in I/R + vehicle group was reduced by 19%, 13%, and 16% at 24 hour; 18%, 19%, and 15% at 1 week; and 42%, 40%, and 30% at 1 month post-I/R, respectively (). The RGCs in I/R + αB-crystallin group were significantly greater than those in I/R ± vehicle group ().

3.2. Protective Effect of αB-Crystallin on the Reduction in Amplitude of a-Wave, b-Wave, and OPs

To investigate the retina functional changes caused by I/R, ERG was recorded 1 week after I/R. Figure 3(a) showed the ERG changes for the three groups 1 week after I/R or sham operation; data was shown in Figure 3(b). Compared with sham group, the amplitudes of a-wave, b-wave, and OPs were significantly decreased by 58%, 75%, and 82%, respectively, in I/R + vehicle group (173.50 ± 12.18 versus 409.25 ± 22.04 μV for a-wave, 201.75 ± 16.21 versus 795.00 ± 31.80 μV for b-wave, and 35.51 ± 1.86 versus 204.51 ± 13.16 μV for OPs) (). The amplitudes of a-wave, b-wave, and OPs in I/R + αB-crystallin group were also lower than those in sham group, but significantly higher than those in I/R + vehicle group (173.50 ± 12.18 versus 312.50 ± 19.96 μV for a-wave, 201.75 ± 16.21 versus 410.00 ± 46.04 μV for b-wave, and 35.51 ± 1.86 versus 49.03 ± 4.54 μV for OPs) ().

3.3. αB-Crystallin Increased the Activity of T-SOD and Inhibited the Level of MDA and NO

To access the effects of αB-crystallin on the activity of retinal cellular antioxidants, the cellular levels of MDA, NO, and T-SOD were shown in Figure 4 and data was recorded in Table 2 at 24 hours and 1 week after retinal I/R injury. At 24 hours after I/R injury, the level of MDA was significantly lower in sham group and I/R + αB-crystallin group compared with I/R + vehicle group (10.58 ± 4.59, 21.40 ± 3.24, and 14.63 ± 2.58 nmol/mg protein, resp., for sham, I/R + vehicle, and I/R + αB-crystallin groups) () (Figure 4(a)). Meanwhile, αB-crystallin significantly decreased the level of NO in I/R + αB-crystallin group (10.02 ± 1.16, 16.47 ± 0.76, and 11.98 ± 1.68 μmol/g protein for sham, I/R + vehicle, and I/R + αB-crystallin groups, resp.) () (Figure 4(b)). We also determined the activity of T-SOD, which was lower in I/R + vehicle group than that in αB-crystallin group (46.35 ± 7.96 versus 68.84 ± 7.93 U/mg protein) () (Figure 4(c)). However, the content of MDA, NO, and T-SOD showed no significant difference between I/R + vehicle and I/R + αB-crystallin groups () at 1 week, which indicated that αB-crystallin can play an antioxidative role at early stage of retinal I/R injury.

GroupMDA (nM/mgprot)NO (μmol/mgprot)T-SOD (U/mgprot)

Sham10.58 ± 4.5910.02 ± 1.1685.78 ± 9.57
24 h I/R + vehicle21.40 ± 3.24a,16.47 ± 0.76a,46.35 ± 7.96a,
24 h I/R + αB-crystallin14.63 ± 2.58b,11.98 ± 1.68b,68.84 ± 7.93b,
1 w I/R + vehicle16.55 ± 1.99a,11.27 ± 2.05a,70.05 ± 3.98a,
1 w I/R + αB-crystallin13.11 ± 2.2111.26 ± 0.9973.96 ± 9.05

aCompared with sham group. bCompared with I/R + vehicle. , each .
3.4. αB-Crystallin Decreased the Expression of iNOS after I/R Injury

Immunohistochemical staining of iNOS was measured at 1 week after I/R injury (). Compared with sham group, positive expression of iNOS was dominant in GCL and IPL in I/R + vehicle group and I/R + αB-crystallin group (). When rats were treated with αB-crystallin, the expression of iNOS was less prominent than that in I/R + vehicle group () (Figure 5(a)). The positive expression of iNOS was compared by ratio of IOD/area in GCL and IPL (Figure 5(b)).

3.5. αB-Crystallin Inhibited the Activation of NF-κB after I/R Injury

NF-κB (p65) might be a vital factor for the I/R injury of organs. Immunohistochemistry staining of NF-κB was measured at 1 week after I/R (). The positive NF-κB was expressed in INL, which was significantly observed in I/R + vehicle group compared with I/R + αB-crystallin group () (Figure 6(a)). The positive cell number of NF-κB was counted and compared by ratio of IOD/area (Figure 6(b)).

4. Discussion

In this study, we revealed that αB-crystallin played a neuroprotective role in a rat model with retinal I/R injury. The results showed that αB-crystallin could decrease the loss of RGCs and prevent IPL, INL, and ONL from becoming thinner. Compared with I/R + vehicle group, the a-wave, b-wave, and OPs decrement could be reduced by αB-crystallin in ERG, which indicated that αB-crystallin could decrease the damage of retinal function caused by I/R. Furthermore, αB-crystallin showed antioxidant effect by attenuating the level of MDA and NO and increasing the activity of T-SOD. Immunohistochemical staining of retinal sections suggested that αB-crystallin could suppress positive expression of iNOS and downregulate activation of NF-κB. These results further demonstrated that αB-crystallin played a protective role in retinal ischemia reperfusion through antioxidant and by suppressing the activation of NF-κB.

Our study had demonstrated that there was significantly decrease of RGCs and thickness of retina at 24 hours, 1 week, and 1 month caused by retina I/R, which was corresponded to previous researches [1922]. And the reduction of IPL and INL thickness were more at early I/R injury stage, which was in good agreement of Ju et al.’s [23] research, and the damage of retinal I/R injury was obvious at 1 month in our study. The induction of cell death within 24 hours of I/R was compatible with the mechanism evoked by the release of ROS [24]. Compared with αB-crystallin given, the thickness of retina was more decreasing in I/R + vehicle at 24 hours, 1 week, and 1 month, which indicated that αB-crystallin can protect retina from I/R injury at early stage, which may be associated with antioxidation.

ERG was a common and sensitive measurement to evaluate retinal function. The a-waves provided information associated with the photoreceptors, as well as b-waves regarding the physiology of the ONL bipolar and Müller cells [25, 26]. And OPs were triggered by amacrine cells [27]. A diminished amplitude of b-wave had been well known as a poor prognostic sign in retina-ischemic reperfusion [2830]. And a large number of studies had indicated that there was a remarkably slower recovery of the b-wave in the high IOP model [1921, 31]. The severe reduction of oscillatory potentials appeared to exist a correlation with a circulatory deficiency in the retina, so the OPs were used to prognose retinal disease, particularly in diabetic retinopathy and ischemia [32]. Whereas these changes were significantly ameliorated by αB-crystallin, when administrated with αB-crystallin, both a- and b-wave amplitudes were improved. Consequently, we inferred that αB-crystallin protected the retina from I/R injury in functional morphology. But it was not clear how αB-crystallin played a protective effect in retinal ischemia reperfusion.

Many studies have revealed irreversible cellular damages caused by retinal I/R. At cellular level, ischemic retinal injury consists of energy failure, glutamate excitability toxicity, calcium overload, inflammation, and oxidative stress, which lead to cell necrosis or apoptosis. It is well known that oxidative stress plays a vital role in I/R injury. MDA is a naturally degraded product of lipid peroxidation, a process which can react with the amino group of nucleic acids to produce cytotoxicity when unsaturated fat-soluble substances (lipids) are oxidized to form radicals [33]. NO is an important neuromediator implicated in many physiological processes in the retina which reacts with superoxide to form peroxynitrite. As a strong oxidant, peroxynitrite causes lipid peroxidation, which leads to DNA damage and makes SOD inactivated [34]. Therefore, the level of MDA and NO is taken as markers of the severity of cellular damage. Meanwhile, the balance of oxidants and antioxidants (e.g., T-SOD and GSH) is responsible for cellular homeostasis [35] and the activity of T-SOD is an indicator for evaluating antioxidant enzyme status. Therefore, the changes of MDA, NO, and T-SOD can reflect the damage of retina caused by oxidative stress during retinal I/R injury.

It has been reported that αB-crystallin belongs to the small heat-shock protein (sHSP) superfamily. In addition to their chaperone functions, several studies have proved that the effects of αB-crystallin are involved in anti-inflammatory, antioxidation, antiapoptosis, and antiangiogenesis [79]. In vitro study, it has shown that αB-crystallin treatment not only suppresses the increase in lipid peroxidation levels but also inhibits the lipid breakdown resulting from auto-oxidation by increasing the activities of SOD in mouse cerebral cortex homogenate [36]. In Romi et al.’s research, αB-crystallin modulates superoxide dismutase-1 (SOD-1) tissue accumulation in familial amyotrophic lateral sclerosis [37]. As known in Huang et al.’s reports, αB-crystallin might be important for myocardial protection during the early phase of ischemic preconditioning, which may associate with attenuating the production of MDA [38]. Wu et al. had suggested that intravenous injection of αB-crystallin could be a possible strategy for the treatment of optic nerve injury by inhibiting TNF-alpha and iNOS protein expression, and iNOS was a subunit of NO [39]. In addition, the significant antioxidation of αB-crystallin had been investigated in retinal pigment epithelium (RPE) by Kannan et al. [9]. Mueller et al. revealed that increasing levels of alpha-crystallin were found in the lens and retina following intravitreal injection of homo- and hetero-oligomers in rats [40]. Besides, accumulating evidences have suggested the neuroprotective effect of exogenous αB-crystallin in the model of rat optic nerve crush [4143]. There were two ways [42, 43] of αB-crystallin given to rats through intravitreal (1 × 10−5 g/L, 5 μL for once) or intravenous injection (50 μg/100 g for 10 times), but no evidence to determine the superiority between them. With regard to the content and given times of αB-crystallin and safety, we determined its protection in rat I/R injury with 5 μL (1 × 10−5 g/L) intravitreously. As reported in our study, the level of MDA and NO significantly reduced and the activity of T-SOD obviously increased when treated with αB-crystallin after retina I/R injury, which indicated that αB-crystallin had an antioxidative effect.

NF-κB, a redox-sensitive transcription factor, plays a critical role in neuronal cell death in retinal I/R injury [18]. And the expression of NF-κB is likely to be instrumental in the upregulation of iNOS, which expresses increasingly in inner retinal layer when subjected to I/R [44]. Recent studies have demonstrated that protecting the retina from ischemia-reperfusion injury can be done by reducing the expression of NF-κB [1618]. And other researches have suggested that increasing expression of αB-crystallin and suppressing activity of NF-κB can play a role in inhibiting apoptosis or neuroinflammation [45, 46]. However, Adhikari et al. demonstrated that phosphorylation of αB-crystallin upregulated the expression of NF-κB to exert its antiapoptosis to protect myoblasts from cytotoxicity when treated with TNF-α [47]. Mercatelli et al. also revealed that skeletal myoblasts could be protected by the activating NF-κB and/or overexpressing αB-crystallin involved in oxidative stress [48]. Then, αB-crystallin directly resists tissue damages by mitigating or activating the expression of NF-κB. In this study, we showed that administration with αB-crystallin diminished the positive expression of iNOS and NF-κB after I/R. Consequently, the finding clarified that αB-crystallin could alleviate NF-κB expression by reducing the amount of iNOS to attenuate the severity of damage induced by I/R.

5. Conclusion

We have demonstrated that αB-crystallin had a neuroprotective effect on the retina after ischemia reperfusion injury through its antioxidant activities and achieved by inhibiting the expression of NF-κB. But our study has some limitations. First, αB-crystallin was administered after the induction of ischemia reperfusion once immediately, which would not indicate the effective period. Second, we only detected that αB-crystallin protected the retina from I/R injury through antioxidant and the signal pathway of NF-κB, but there are further signal pathways that deserved to be investigated. Generally, our available data indicate that αB-crystallin can be a potential therapeutic drug for retinal I/R-related diseases.

Conflicts of Interest

The authors declare no competing interests related to this manuscript.

Authors’ Contributions

Huan Yan and Yanli Peng contributed equally to this work.


This work was supported by the Health Bureau of Chongqing (Grant 2013-2-043). The authors thank Weiyang Shao, Jiaman Dai, and Yuxiao Zeng (Laboratory of Ophthalmology, Xinan Hospital, Third Military Medical University) for the technical support and Yongqiang Tang (Ophthalmology Department, The Second Affiliated Hospital of Chongqing Medical University) for abundant discussions.


  1. Y. Zhang, Z. Zhang, and H. Yan, “Simvastatin inhibits ischemia/reperfusion injury-induced apoptosis of retinal cells via downregulation of the tumor necrosis factor-α/nuclear factor-κB pathway,” International Journal of Molecular Medicine, vol. 36, no. 2, pp. 399–405, 2015. View at: Publisher Site | Google Scholar
  2. A. Shimouchi, H. Yokota, S. Ono et al., “Neuroprotective effect of water-dispersible hesperetin in retinal ischemia reperfusion injury,” Japanese Journal of Ophthalmology, vol. 60, no. 1, pp. 51–61, 2016. View at: Publisher Site | Google Scholar
  3. N. N. Osborne, R. J. Casson, J. P. Wood, G. Chidlow, M. Graham, and J. Melena, “Retinal ischemia: mechanisms of damage and potential therapeutic strategies,” Progress in Retinal and Eye Research, vol. 23, no. 1, pp. 91–147, 2004. View at: Publisher Site | Google Scholar
  4. M. L. Robinson and P. A. Overbeek, “Differential expression of alpha A- and alpha B-crystallin during murine ocular development,” Investigative Ophthalmology & Visual Science, vol. 37, no. 11, pp. 2276–2284, 1996. View at: Google Scholar
  5. J. Horwitz, M. P. Bova, L. L. Ding, D. A. Haley, and P. L. Stewart, “Lens α-crystallin: function and structure,” Eye, vol. 13, Part 3b, pp. 403–408, 1999. View at: Publisher Site | Google Scholar
  6. S. P. Bhat and C. N. Nagineni, “αB subunit of lens-specific protein α-crystallin is present in other ocular and non-ocular tissues,” Biochemical and Biophysical Research Communications, vol. 158, no. 1, pp. 319–325, 1989. View at: Publisher Site | Google Scholar
  7. R. S. McGreal, W. L. Kantorow, D. C. Chauss, J. Wei, L. A. Brennan, and M. Kantorow, “αB-crystallin/sHSP protects cytochrome c and mitochondrial function against oxidative stress in lens and retinal cells,” Biochimica et Biophysica Acta (BBA) - General Subjects, vol. 1820, no. 7, pp. 921–930, 2012. View at: Publisher Site | Google Scholar
  8. S. Kase, S. He, S. Sonoda et al., “αB-crystallin regulation of angiogenesis by modulation of VEGF,” Blood, vol. 115, no. 16, pp. 3398–3406, 2010. View at: Publisher Site | Google Scholar
  9. R. Kannan, P. G. Sreekumar, and D. R. Hinton, “Novel roles for α-crystallins in retinal function and disease,” Progress in Retinal and Eye Research, vol. 31, no. 6, pp. 576–604, 2012. View at: Publisher Site | Google Scholar
  10. J. B. Velotta, N. Kimura, S. H. Chang et al., “αB-crystallin improves murine cardiac function and attenuates apoptosis in human endothelial cells exposed to ischemia-reperfusion,” The Annals of Thoracic Surgery, vol. 91, no. 6, pp. 1907–1913, 2011. View at: Publisher Site | Google Scholar
  11. T. Li, X. Mo, Z. Jiang et al., “Study of αB-crystallin expression in gerbil BCAO model of transient global cerebral ischemia,” Oxidative Medicine and Cellular Longevity, vol. 2012, Article ID 945071, 7 pages, 2012. View at: Publisher Site | Google Scholar
  12. X. Ying, J. Zhang, Y. Wang, N. Wu, Y. Wang, and D. T. Yew, “α-crystallin protected axons from optic nerve degeneration after crushing in rats,” Journal of Molecular Neuroscience, vol. 35, no. 3, pp. 253–258, 2008. View at: Publisher Site | Google Scholar
  13. S. Thanos, M. R. Bohm, M. Meyer zu Horste et al., “Role of crystallins in ocular neuroprotection and axonal regeneration,” Progress in Retinal and Eye Research, vol. 42, pp. 145–161, 2014. View at: Publisher Site | Google Scholar
  14. Y. Munemasa, J. M. Kwong, J. Caprioli, and N. Piri, “The role of αA- and αB-crystallins in the survival of retinal ganglion cells after optic nerve axotomy,” Investigative Ophthalmology & Visual Science, vol. 50, no. 8, pp. 3869–3875, 2009. View at: Publisher Site | Google Scholar
  15. Z. Wu, L. Wang, and S. Hou, “Alpha B-crystallin improved survival of retinal ganglion cells in a rat model of acute ocular hypertension,” Neural Regeneration Research, vol. 7, no. 19, pp. 1493–1497, 2012. View at: Publisher Site | Google Scholar
  16. T. Masuda, M. Shimazawa, F. Ishizuka, S. Nakamura, K. Tsuruma, and H. Hara, “Tissue kallikrein (kallidinogenase) protects against retinal ischemic damage in mice,” European Journal of Pharmacology, vol. 738, pp. 74–82, 2014. View at: Publisher Site | Google Scholar
  17. H. S. Ozacmak, V. H. Ozacmak, F. Barut, M. Araslı, and B. H. Ucan, “Pretreatment with mineralocorticoid receptor blocker reduces intestinal injury induced by ischemia and reperfusion: involvement of inhibition of inflammatory response, oxidative stress, nuclear factor κB, and inducible nitric oxide synthase,” The Journal of Surgical Research, vol. 191, no. 2, pp. 350–361, 2014. View at: Publisher Site | Google Scholar
  18. F. T. Chen, C. M. Yang, and C. H. Yang, “The protective effects of the proteasome inhibitor bortezomib (velcade) on ischemia-reperfusion injury in the rat retina,” PLoS One, vol. 8, no. 5, article e64262, 2013. View at: Publisher Site | Google Scholar
  19. N. Tong, Z. Zhang, Y. Gong, L. Yin, and X. Wu, “Diosmin protects rat retina from ischemia/reperfusion injury,” Journal of Ocular Pharmacology and Therapeutics, vol. 28, no. 5, pp. 459–466, 2012. View at: Publisher Site | Google Scholar
  20. W. C. Tasi, S. M. Petersen-Jones, P. Y. Huang, and C. T. Lin, “The neuroprotective effects of lidocaine and methylprednisolone in a rat model of retinal ischemia-reperfusion injury,” The Journal of Veterinary Medical Science, vol. 74, no. 3, pp. 307–313, 2012. View at: Publisher Site | Google Scholar
  21. Z. Zhang, X. Qin, X. Zhao et al., “Valproic acid regulates antioxidant enzymes and prevents ischemia/reperfusion injury in the rat retina,” Current Eye Research, vol. 37, no. 5, pp. 429–437, 2012. View at: Publisher Site | Google Scholar
  22. L. Chen, Y. Qi, and X. Yang, “Neuroprotective effects of crocin against oxidative stress induced by ischemia/reperfusion injury in rat retina,” Ophthalmic Research, vol. 54, no. 3, pp. 157–168, 2015. View at: Publisher Site | Google Scholar
  23. W. K. Ju, K. Y. Kim, S. J. Park et al., “Nitric oxide is involved in sustained and delayed cell death of rat retina following transient ischemia,” Brain Research, vol. 881, no. 2, pp. 231–236, 2000. View at: Publisher Site | Google Scholar
  24. M. E. Szabo, M. T. Droy-Lefaix, M. Doly, C. Carré, and P. Braquet, “Ischemia and reperfusion-induced histologic changes in the rat retina. Demonstration of a free radical-mediated mechanism,” Investigative Ophthalmology & Visual Science, vol. 32, no. 5, pp. 1471–1478, 1991. View at: Google Scholar
  25. R. P. Kline, H. Ripps, and J. E. Dowling, “Generation of b-wave currents in the skate retina,” Proceedings of the National Academy of Sciences of the United States of America, vol. 75, no. 11, pp. 5727–5731, 1978. View at: Publisher Site | Google Scholar
  26. E. Dick and R. F. Miller, “Light-evoked potassium activity in mudpuppy retina: its relationship to the b-wave of the electroretinogram,” Brain Research, vol. 154, no. 2, pp. 388–394, 1978. View at: Publisher Site | Google Scholar
  27. L. Wachtmeister, “Oscillatory potentials in the retina: what do they reveal,” Progress in Retinal and Eye Research, vol. 17, no. 4, pp. 485–521, 1998. View at: Publisher Site | Google Scholar
  28. M. Tsimpida, D. A. Thompson, A. Liasis et al., “Visual outcomes following intraophthalmic artery melphalan for patients with refractory retinoblastoma and age appropriate vision,” The British Journal of Ophthalmology, vol. 97, no. 11, pp. 1464–1470, 2013. View at: Publisher Site | Google Scholar
  29. S. I. Savitz, M. S. Dhallu, S. Malhotra et al., “EDG receptors as a potential therapeutic target in retinal ischemia-reperfusion injury,” Brain Research, vol. 1118, no. 1, pp. 168–175, 2006. View at: Publisher Site | Google Scholar
  30. O. Kjeka, R. W. Jansson, C. Bredrup, and J. Krohn, “Early panretinal photocoagulation for ERG-verified ischaemic central retinal vein occlusion,” Acta Ophthalmologica, vol. 91, no. 1, pp. 37–41, 2013. View at: Publisher Site | Google Scholar
  31. I. M. Fang, C. M. Yang, and C. H. Yang, “Chitosan oligosaccharides prevented retinal ischemia and reperfusion injury via reduced oxidative stress and inflammation in rats,” Experimental Eye Research, vol. 130, pp. 38–50, 2015. View at: Publisher Site | Google Scholar
  32. P. Speros and J. Price, “Oscillatory potentials. History, techniques and potential use in the evaluation of disturbances of retinal circulation,” Survey of Ophthalmology, vol. 25, no. 4, pp. 237–252, 1981. View at: Publisher Site | Google Scholar
  33. R. E. Anderson, M. B. Maude, and J. C. Nielsen, “Effect of lipid peroxidation on rhodopsin regeneration,” Current Eye Research, vol. 4, no. 1, pp. 65–71, 1985. View at: Publisher Site | Google Scholar
  34. D. S. Warner, H. Sheng, and I. Batinic-Haberle, “Oxidants, antioxidants and the ischemic brain,” The Journal of Experimental Biology, vol. 207, Part 18, pp. 3221–3231, 2004. View at: Publisher Site | Google Scholar
  35. P. Korge, G. Calmettes, and J. N. Weiss, “Increased reactive oxygen species production during reductive stress: the roles of mitochondrial glutathione and thioredoxin reductases,” Biochimica et Biophysica Acta (BBA) - Bioenergetics, vol. 1847, no. 6-7, pp. 514–525, 2015. View at: Publisher Site | Google Scholar
  36. J. G. Masilamoni, E. P. Jesudason, S. N. Bharathi, and R. Jayakumar, “The protective effect of α-crystallin against acute inflammation in mice,” Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol. 1740, no. 3, pp. 411–420, 2005. View at: Publisher Site | Google Scholar
  37. F. Romi, G. Helgeland, and N. E. Gilhus, “Heat-shock proteins in clinical neurology,” European Neurology, vol. 66, no. 2, pp. 65–69, 2011. View at: Publisher Site | Google Scholar
  38. Q. Huang, W. M. Xiao, J. L. You, X. Z. Xiao, and L. Zhong, “The roles of alpha B-crystallin during early phase of myocardial ischemic preconditioning in rats,” Bulletin of Hunan Medical University, vol. 25, no. 3, pp. 219–222, 2000. View at: Google Scholar
  39. N. Wu, J. Yu, S. Chen et al., “α-crystallin protects RGC survival and inhibits microglial activation after optic nerve crush,” Life Sciences, vol. 94, no. 1, pp. 17–23, 2014. View at: Publisher Site | Google Scholar
  40. N. H. Mueller, U. Fogueri, M. G. Pedler, K. Montana, J. M. Petrash, and D. A. Ammar, “Impact of subunit composition on the uptake of α-crystallin by lens and retina,” PLoS One, vol. 10, no. 9, article e0137659, 2015. View at: Publisher Site | Google Scholar
  41. Y. Jia, “Effects of intravenous injection of α-crystallin on retinal ganglion cells and some important organs,” Chinese Journal of Ocular Fundus Diseases, vol. 27, no. 2, pp. 163–166, 2011. View at: Google Scholar
  42. W. Rui, Protective Effect of Recombinant Human Alpha-Crystallin B on Optic Nerve Injury in Rat, Third Military Medical University, Chongqing, China, 2011.
  43. L. Zhingmin, “Protective effects of mixed crystallin on injured retinal ganglion cells after optic nerve injury in Long-Evans rats,” Chinese Journal of Trauma, vol. 22, no. 12, 2006. View at: Google Scholar
  44. P. Lipton, “Ischemic cell death in brain neurons,” Physiological Reviews, vol. 79, no. 4, pp. 1431–1568, 1999. View at: Google Scholar
  45. S. Bharti, N. Rani, J. Bhatia, and D. S. Arya, “5-HT2B receptor blockade attenuates β-adrenergic receptor-stimulated myocardial remodeling in rats via inhibiting apoptosis: role of MAPKs and HSPs,” Apoptosis, vol. 20, no. 4, pp. 455–465, 2015. View at: Publisher Site | Google Scholar
  46. Y. Zhang, Y. Chen, J. Wu et al., “Activation of dopamine D2 receptor suppresses neuroinflammation through αB-Crystalline by inhibition of NF-κB nuclear translocation in experimental ICH mice model,” Stroke, vol. 46, no. 9, pp. 2637–2646, 2015. View at: Publisher Site | Google Scholar
  47. A. S. Adhikari, B. N. Singh, K. S. Rao, and C. M. Rao, “αB-crystallin, a small heat shock protein, modulates NF-κB activity in a phosphorylation-dependent manner and protects muscle myoblasts from TNF-α induced cytotoxicity,” Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, vol. 1813, no. 8, pp. 1532–1542, 2011. View at: Publisher Site | Google Scholar
  48. N. Mercatelli, I. Dimauro, S. A. Ciafre, M. G. Farace, and D. Caporossi, “αB-crystallin is involved in oxidative stress protection determined by VEGF in skeletal myoblasts,” Free Radical Biology and Medicine, vol. 49, no. 3, pp. 374–382, 2010. View at: Publisher Site | Google Scholar

Copyright © 2017 Huan Yan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2021, as selected by our Chief Editors. Read the winning articles.